Showing results 1 to 5 of 5
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody Lee, Ji Min; Kim, B.; Lee, S. B.; Jeong, Y.; Oh, Y. M.; Song, Y-J; Jung, S.; et al, ONCOGENE, v.33, no.1, pp.34 - 43, 2014-01 |
Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee, Jeeyun; Ou, Sai-Hong Ignatius; Lee, Ji Min; Kim, Hee Cheol; Hong, Mineui; Kim, Sun Young; Jang, Jiryeon; et al, ONCOTARGET, v.6, no.29, pp.28211 - 28222, 2015-09 |
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy Kim, B.; Wang, S.; Lee, Ji Min; Jeong, Y.; Ahn, T.; Son, D-S; Park, H. W.; et al, ONCOGENE, v.34, no.9, pp.1083 - 1093, 2015-02 |
The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer Lee, Bok-Soon; Kim, Haeng-Jun; Hwang, Jae-Woong; Cheong, Kwang Ho; Kim, Kyung-Ah; Cha, Hyun-Young; Lee, Ji Min; et al, ANNALS OF SURGICAL ONCOLOGY, v.23, no.6, pp.2046 - 2053, 2016-06 |
USP8 modulates ubiquitination of LRIG1 for Met degradation Oh, Young Mi; Lee, Saet Byoul; Choi, Jaehyun; Suh, Hye-Young; Shim, Seonhui; Song, Yun-Jeong; Kim, Bogyou; et al, SCIENTIFIC REPORTS, v.4, 2014-05 |
Discover